| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Anti-T7 tag antibody. T7 Tag Peptide is an epitope tag recognized by commercially available anti-T7 tag antibodies. It is not a drug target; rather, it is a tool for detecting and purifying recombinant proteins. The peptide can be used as a blocking reagent, a positive control in Western blots or ELISA, or as a competitor in antibody binding studies.
|
|---|---|
| ln Vitro |
In vitro, T7 Tag Peptide is used to confirm the specificity of anti-T7 tag antibodies. It can compete with T7-tagged proteins for antibody binding, allowing validation of antibody specificity. It is not intended to have any biological activity on cells. The TFA salt ensures the peptide is readily soluble in aqueous buffers for assay use.
|
| ln Vivo |
Not applicable. T7 Tag Peptide TFA is not administered to animals as a therapeutic or diagnostic agent. It is used exclusively as a laboratory reagent in protein biochemistry and immunoassays. It may be used in animal studies as a positive control for antibody injections if immunized against T7 tag, but this is rare.
|
| Enzyme Assay |
T7 tag antibody binding assay (ELISA): A microplate is coated with T7 Tag Peptide TFA (0.1-10 ug/mL) overnight at 4degC. After blocking, increasing concentrations of anti-T7 tag antibody (0-1000 ng/mL) are added and detected with an HRP-labeled secondary antibody. Alternatively, the peptide can be used as a competitor: antibody is pre-incubated with soluble peptide before adding to a plate coated with T7-tagged protein to determine IC50.
|
| Cell Assay |
Cell-based protein detection: Cells are transfected with a T7-tagged expression vector. After 24-48 h, cell lysates are prepared. For Western blot, the lysates are electrophoresed and transferred, then the membrane is incubated with anti-T7 tag antibody. A parallel control lane can be treated with T7 Tag Peptide TFA during antibody incubation to confirm band specificity (competitive blocking). For immunoprecipitation, the peptide can be used for elution.
|
| Animal Protocol |
Not applicable for direct in vivo use. In some models, T7-tagged proteins are administered to mice, and T7 Tag Peptide TFA can be used to block the tag for control purposes, but this is uncommon. The primary use is in vitro as a biochemical tool.
|
| ADME/Pharmacokinetics |
Not applicable. T7 Tag Peptide TFA is a research reagent, not a therapeutic drug. It is soluble in water and common buffers. The TFA salt is used to improve handling and stability. For storage, keep the lyophilized powder at -20degC, desiccated.
|
| Toxicity/Toxicokinetics |
The peptide is non-toxic at the concentrations used in vitro (typically 0.1-10 ug/mL). It is not intended for human or animal consumption. Standard safety precautions for handling laboratory peptides should be followed.
|
| References |
[1]. Tsutomu Tanaka, et al. A Peptidyl Linker for Protein Cross-Linking Catalyzed by Microbial Transglutaminase. The Society of Chemical Engineers, Japan. Session ID : 3J-11.
|
| Additional Infomation |
T7 Tag Peptide TFA is a research-grade epitope tag reagent. It is not a drug and has no therapeutic indications. The sequence is MASMTGGQQMG. It is widely used in molecular biology, protein purification, and detection. For research use only. Store at -20degC, protected from light and moisture.
|
| Molecular Formula |
C43H72F3N13O18S3
|
|---|---|
| Related CAS # |
T7 Tag Peptide;245445-88-9
|
| Sequence |
MASMTGGQQMG
|
| Appearance |
White to off-white solid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~50 mg/mL (~41.24 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (2.06 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (2.06 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (2.06 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of corn oil and mix well.  (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.